

## **Disclosure of conflict of interest**

Faculty members have been asked to disclose any potential conflict of interest in relation to their participation in the above mentioned event. Potential conflict of interest are considered any of the following:

- Any financial interest in or arrangement with a company whose products or services are discussed in the lecture or that might be considered as part of the statement process;
- Any financial interest in or arrangement with a competing company;
- Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in the work presented or in the participation in the statement process, including pertinent commercial or other sources of funding for the speaker or panellist or for the associated department or organisation, personal relationships or direct academic competition.

### **T. Albreht:**

*Recipient of honoraria or consultation fees: Pfizer*

**M. Angi:** *No significant relationships*

**G. Arrivi:** *No significant relationships*

**S. Aust:** *No significant relationships*

### **J. Balmana:**

*Recipient of grants/research supports: Astra Zeneca*

*Recipient of honoraria or consultation fees: Astra Zeneca, Pfizer*

**A. Berruti:** *Form not received*

### **J. Blay:**

*Recipient of grants/research supports: Roche, Bayer, MSD, BMS, Pharmamar, Deciphera*

*Recipient of honoraria or consultation fees: Roche, Bayer, MSD, BMS, Pharmamar, Deciphera*

*Stock/shareholder: Innate pharma*

### **J. Capdevila:**

*Recipient of grants/research supports: Eisai, Astrazeneca, AAA, Ipsen, Pfizer, Novartis*

*Recipient of honoraria or consultation fees: Amgen, Bayer, Eisai, AAA, Ipsen,*

*Pfizer, Merck, Sanofi, Novartis*

*Participation in a sponsored speakers' bureau: Amgen, Bayer, Eisai, AAA, Ipsen,*

*Pfizer, Merck, Sanofi, Novartis*

### **M. Caplin:**

*Recipient of grants/research supports: AAA-NOVARTIS; IPSEN*

*Recipient of honoraria or consultation fees: AAA-NOVARTIS; IPSEN; SIRTEX*

*Participation in a sponsored speakers' bureau: AAA-NOVARTIS; IPSEN; SIRTEX; PFIZER*

### **P. Casali:**

*Recipient of grants/research supports: At my institution, my Unit received funds from: Advenchen Laboratories, Amgen Dompé, AROG Pharmaceuticals, Bayer, Blueprint Medicines, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Epizyme Inc, Glaxo, Karyopharm Pharmaceuticals, Novartis, Pfizer, Pha*

*Recipient of honoraria or consultation fees: Honoraria for speaker, consultancy/advisory role from: Bayer, Deciphera, Eisai, Eli Lilly, Pfizer.*

**S. Cavaliere:** *No significant relationships*

**E. Colombo:** *No significant relationships*

### **F. De Braud:**

*Recipient of honoraria or consultation fees: Ignyta, BMS, Daiichi Sankyo, Pfizer, Octimet Oncology, Incyte, Teofarma, Pierre Fabre, Roche, EMD Serono, Sanofi, NMS Nerviano Medical Science, Pharm Research Associated (U.K) Ltd*

*Participation in a sponsored speakers' bureau: BMS, Roche, MSD, Ignyta, Bayer, ACCMED, Dephaforum S.r.l., Nadirex, Merck, Biotechspert Ltd, PriME Oncology, Pfizer, Servier, Celgene, Tesaro, Loxo Oncology Inc., Sanofi, Healthcare Research & Pharmacoeconomics*

**L. De Cecco:** *Form not received*

**C. de la Fouchardiere:** *Form not received*

**F. De Lorenzo:** *No significant relationships*

**M. Deraco:** *No significant relationships*

**N. Fazio:**

*Recipient of grants/research supports:* Ipsen, AAA, Novartis, Merck

*Recipient of honoraria or consultation fees:* Ipsen, Novartis, Pfizer, Sanofi, AAA, Merck, MSD, Wren Laboratories

**S. Franceschi:** *No significant relationships*

**A. Frezza:** *No significant relationships*

**G. Galli:** *No significant relationships*

**M. Garassino:**

*Recipient of grants/research supports:* GlaxoSmithKline - Spectrum Pharmaceuticals-Novartis-AstraZeneca-MedImmune-Merck-Blueprint Medicines-Bristol-Myers Squibb-Amgen-Sanofi-Exelixis-Janssen-Takeda-Roche/Genentech- Incyte-Ipsen-MSD-Pfizer

*Recipient of honoraria or consultation fees:* Tiziana Life Sciences-Incyte- MSD-Seattle Genetics-GlaxoSmithKline-Bristol-Myers Squibb - Daiichi Sankyo- Pfizer- Bayer- Novartis- Takeda- Janssen-Sanofi- - Inivata -Blueprint Medicines-Celgene-Eli Lilly-Roche-AstraZeneca-

*Participation in a sponsored speakers' bureau:* Bristol-Myers Squibb- Takeda- Eli Lilly-AstraZeneca-Celgene- Roche-MSD Oncology- Otsuka- Incyte

*Travel, Accommodations, Expenses:* Roche- Pfizer- AstraZeneca

**J. Gietema:** *Form not received*

**R. Glynne-Jones:** *No significant relationships*

**V. Gregoire:** *No significant relationships*

**A. Gronchi:**

*Recipient of grants/research supports:* PharmaMar

*Recipient of honoraria or consultation fees:* Novartis, Pfizer, Bayer, Lilly, SpringWorks, PharmaMar, Nanobiotix

**E. Kapiteijn:** *No significant relationships*

**H. Klumpen:** *No significant relationships*

**R. Ladenstein:** *No significant relationships*

**C. Lebbé:**

*Recipient of grants/research supports:* Roche, BMS

*Recipient of honoraria or consultation fees:* Roche, BMS, Amgen, MSD, Pierre Fabre, Pfizer, Incyte

*Participation in a sponsored speakers' bureau:* Roche, BMS, Novartis, Amgen

**L. Licitra:**

*Recipient of grants/research supports:* Funds received by my institution for clinical studies and research activities in which I am involved: Astrazeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis inc, Hoffmann-La Roche Ltd, IRX Therapeutics inc, Medpace inc, Merc  
*Recipient of honoraria or consultation fees:* Astrazeneca, Bayer, BMS, Eisai, MSD, Merck-Serono, Boehringer Ingelheim, Novartis, Roche, Debiopharm, Sobi, Incyte Biosciences Italy srl, Doxa Pharma, Amgen, Nanobiotics Sa, GSK.

*For public speaking/teaching from research companies & commercial education providers:* AccMed, Medical Science Foundation G. Lorenzini, Associazione Sinapsi, Think 2 IT, Aiom Servizi, Prime Oncology, WMA Congress Education, Fasi, DueCi promotion Srl, MI&T, Net Congress & Education, PRMA Consulting, Kura Oncology, Health & Life srl, Ipse

**L. Locati:** *Form not received*

**D. Lorusso:**

*Recipient of grants/research supports:* gsk, Pharmamar, MSD

*Recipient of honoraria or consultation fees:* GSK, Pharmamar, MSD, Clovis, Astra Zeneca, Amgen, Merck

*Participation in a sponsored speakers' bureau:* GSK, Astra Zeneca, Clovis

**A. Necchi:**

*Recipient of grants/research supports:* Merck, Astra Zeneca, Ipsen, BMS

*Recipient of honoraria or consultation fees:* Merck, Bayer, Janssen, BMS, Astra Zeneca, Seattle Genetics, Incyte, Rainier Therapeutics

*Spouse/partner:* Bayer

**M. Niger:**

*Recipient of honoraria or consultation fees:* EMD Serono

*Participation in a sponsored speakers' bureau:* Accademia della Medicina, IQVIA

*travel and meeting expenses:* celgene

**K. Oliver:** Form not received

**F. Peccatori:** No significant relationships

**A. Pellerino:** No significant relationships

**C. Piazza:** No significant relationships

**S. Piperno-Neumann:** No significant relationships

**I. Ray-Coquard:** Form not received

**C. Resteghini:**

*Recipient of honoraria or consultation fees:* SUNPHARMA

**M. Seckl:** No significant relationships

**C. Simon:**

*Recipient of grants/research supports:* From Intuitive and Roche

*Recipient of honoraria or consultation fees:* From Pfizer, MERCK, MSD, and Seattle Genetics

**R. Soffiatti:**

*Recipient of grants/research supports:* MSD, Roche, Merck Serono, Celldex Therapeutics, Novartis, Mundipharma, PUMA Technologies Inc.

*Recipient of honoraria or consultation fees:* MSD, Roche, Merck Serono, Celldex Therapeutics, Novartis, Mundipharma, PUMA Technologies Inc..

**S. Stacchiotti:**

*Recipient of grants/research supports:* Institutional financial interests: Advenchen, Amgen Dompè, Bayer, Daiichi Sankyo, Epizyme, Eli Lilly, Glaxo, Karyopharm, Novartis, Pfizer, Pharmamar, SpringWorks

*Recipient of honoraria or consultation fees:* Personal financial interests (honoraria, consultancy or advisory role): Bavarian Nordic, Bayer, Epizyme, Eli Lilly, Daiichi Sankyo, Deciphera, Glaxo, Karyopharm, Maxivax, Pharmamar, Takeda

*Travel coverage from::* PharmaMar

**R. Stahel:**

*Recipient of grants/research supports:* AstraZeneca, BMS, Boehringer Ingelheim, Genentech, MSD, Roche, and Pfizer.

*Recipient of honoraria or consultation fees:* Abbvie, Astra Zeneca, BMS, Janssen, MSD, Pfizer, Regeneron, Roche, Seattle Genetics and Takeda

*Participation in a sponsored speakers' bureau:* Amgen, Astra Zeneca, Blueprint, Boehringer Ingelheim, Eli Lilly, GSK, MSD, Novartis and Roche

*DMC:* Genentech/Roche and Takeda

**S. Strauss:** No significant relationships

**T. Tong:** No significant relationships

**A. Trama:** No significant relationships

**M. Van den Bent:**

*Recipient of honoraria or consultation fees:* Geneta, Agios, Abbvie, Bayer, Carthera, Karyopharm, Nerviano, Cellgene

**L. Wyrwicz:** Form not received